A detailed history of Gateway Investment Advisers LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 76,827 shares of GILD stock, worth $6.78 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
76,827
Previous 77,089 0.34%
Holding current value
$6.78 Million
Previous $5.29 Million 21.74%
% of portfolio
0.07%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$66.59 - $83.99 $17,446 - $22,005
-262 Reduced 0.34%
76,827 $6.44 Million
Q2 2024

Jul 12, 2024

SELL
$63.15 - $72.88 $8,525 - $9,838
-135 Reduced 0.17%
77,089 $5.29 Million
Q1 2024

Apr 12, 2024

SELL
$71.58 - $87.29 $8,589 - $10,474
-120 Reduced 0.16%
77,224 $5.66 Million
Q4 2023

Jan 09, 2024

SELL
$73.27 - $83.09 $10,037 - $11,383
-137 Reduced 0.18%
77,344 $6.27 Million
Q3 2023

Oct 19, 2023

SELL
$73.94 - $80.67 $65,510 - $71,473
-886 Reduced 1.13%
77,481 $5.81 Million
Q2 2023

Jul 13, 2023

SELL
$76.01 - $86.7 $101,473 - $115,744
-1,335 Reduced 1.67%
78,367 $6.04 Million
Q1 2023

Apr 11, 2023

BUY
$77.31 - $88.08 $12,678 - $14,445
164 Added 0.21%
79,702 $6.61 Million
Q4 2022

Jan 13, 2023

BUY
$62.32 - $89.47 $382,208 - $548,719
6,133 Added 8.36%
79,538 $0
Q3 2022

Oct 07, 2022

SELL
$59.54 - $68.01 $375,518 - $428,939
-6,307 Reduced 7.91%
73,405 $4.53 Million
Q2 2022

Jul 13, 2022

BUY
$57.72 - $65.01 $57,835 - $65,140
1,002 Added 1.27%
79,712 $4.93 Million
Q1 2022

Apr 14, 2022

SELL
$57.92 - $72.58 $60,294 - $75,555
-1,041 Reduced 1.31%
78,710 $4.68 Million
Q4 2021

Jan 14, 2022

SELL
$64.88 - $73.64 $92,843 - $105,378
-1,431 Reduced 1.76%
79,751 $5.79 Million
Q3 2021

Oct 22, 2021

SELL
$67.69 - $73.03 $261,148 - $281,749
-3,858 Reduced 4.54%
81,182 $5.67 Million
Q2 2021

Jul 13, 2021

SELL
$63.47 - $69.35 $46,650 - $50,972
-735 Reduced 0.86%
85,040 $5.86 Million
Q1 2021

Apr 14, 2021

SELL
$60.0 - $68.46 $57,540 - $65,653
-959 Reduced 1.11%
85,775 $5.54 Million
Q4 2020

Jan 14, 2021

BUY
$56.65 - $64.55 $63,504 - $72,360
1,121 Added 1.31%
86,734 $5.05 Million
Q3 2020

Oct 19, 2020

SELL
$62.1 - $78.08 $421,100 - $529,460
-6,781 Reduced 7.34%
85,613 $5.41 Million
Q2 2020

Jul 15, 2020

SELL
$72.34 - $84.0 $762,752 - $885,696
-10,544 Reduced 10.24%
92,394 $7.11 Million
Q1 2020

Apr 13, 2020

SELL
$62.63 - $80.22 $29.9 Million - $38.3 Million
-476,846 Reduced 82.25%
102,938 $7.7 Million
Q4 2019

Jan 09, 2020

SELL
$61.62 - $67.78 $7.53 Million - $8.29 Million
-122,278 Reduced 17.42%
579,784 $37.7 Million
Q3 2019

Oct 15, 2019

SELL
$62.51 - $69.0 $2.4 Million - $2.65 Million
-38,465 Reduced 5.19%
702,062 $44.5 Million
Q2 2019

Jul 17, 2019

SELL
$61.87 - $69.38 $585,413 - $656,473
-9,462 Reduced 1.26%
740,527 $50 Million
Q1 2019

Apr 10, 2019

BUY
$62.53 - $70.05 $1.46 Million - $1.63 Million
23,310 Added 3.21%
749,989 $48.8 Million
Q4 2018

Jan 14, 2019

SELL
$60.54 - $79.0 $16,103 - $21,014
-266 Reduced 0.04%
726,679 $45.5 Million
Q3 2018

Oct 16, 2018

SELL
$71.28 - $78.92 $194,451 - $215,293
-2,728 Reduced 0.37%
726,945 $56.1 Million
Q2 2018

Jul 11, 2018

SELL
$64.88 - $75.68 $366,701 - $427,743
-5,652 Reduced 0.77%
729,673 $51.7 Million
Q1 2018

Apr 12, 2018

SELL
$72.84 - $88.8 $3.17 Million - $3.86 Million
-43,465 Reduced 5.58%
735,325 $55.4 Million
Q4 2017

Jan 17, 2018

SELL
$71.15 - $83.52 $3.26 Million - $3.82 Million
-45,771 Reduced 5.55%
778,790 $55.8 Million
Q3 2017

Oct 16, 2017

BUY
$72.11 - $85.47 $59.5 Million - $70.5 Million
824,561
824,561 $66.8 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Gateway Investment Advisers LLC Portfolio

Follow Gateway Investment Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.